



Giant cell glioblastoma (GCG) is considered to be a subtype 
of glioblastoma multiforme (GBM). This malignant tumor 
of glial origin is a grade IV tumor according to the current 
classification of the World Health organization (WHo, [1]) 
and accounts for approximately 5% of GBMs and 0.8% 
of all brain tumors [2]. In pediatric patients supratentorial 
tumors are less common than infratentorial tumors with a 
ratio of approximately 1:2. The GBMs account for 7–9% 
of all intracranial tumors and 0.6–7.9% of all GBMs occur 
during childhood [3]. These statistics demonstrate that GCG 
is an exceedingly rare tumor mainly described in isolated 
case reports or series with a predilection for younger pati-
ents [2, 4]. The GCGs arise from white matter, as do the 
common GBMs and have a tendency to involve the fron-
tal and temporal lobes [2, 5]. The higher predilection for 
the cerebral hemispheres than a typical GBM, probably in 
addition to histological variations, may be responsible for 
the better prognosis as the location means that gross total 
resection is more frequent. The tumor is macroscopically 
well-circumscribed and histologically shows numerous 
bizarre multinucleated giant cells with an abundant reticu-
lin network and a high frequency of p53 mutations [6, 7]. 
In general terms GBM has a poor prognosis with a mean 
survival time ranging from 12–15 months in adults [8]. In 
pediatric patients with high grade astrocytoma the outcome 
is slightly better but still remains poor with survival times 
ranging from 15–42 months [9, 10]. In standard GBM tre-
atment protocols tumor resection is followed by irradiation 
and dnA alkylating chemotherapy. Adding temozolomide 
as a chemotherapy drug significantly improved outcome 
in newly diagnosed GBM [11, 12] and the median survi-
val time improved from 12.1 to 14.6 months and the 2-year 
survival rate reached 25.6% compared to 10.4% previously 
when adding temozolomide to standard GBM treatment 
protocols [13, 14]. other factors associated with decreased 
survival in GBM include but are not limited to larger tumor 
size [15], higher age [16] as well as bilateral location [17]. 
The GCG is associated with longer survival times compared 
to GBM, ranging from 15 months up to 17 years in adults [5, 
18] and ranging from 14 months up to 12 years in children 
[4, 19].one case report also reported a long-term survival 
with a late transformation to gliosarcoma [6].
Case Report
This article reports the case of an 8-year-old boy presenting 
at the university hospital with vomiting and a seizure last-
ing approximately 2 min. A second generalized seizure was 
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observed later the same day. Magnetic resonance imaging 
(MrI) was performed on a 1.5 T Magnetom symphony 
scanner (siemens Medical systems, erlangen, Germany) 
with the following imaging parameters: T2-weighted 
sequence Tr/Te = 4920/104 ms, T1-contrast-enhanced 
sequence Tr/Te = 663/17 ms, T1-fat-saturated contrast- 
enhanced sequence Tr/Te = 559/17 ms, diffusion-weighted 
imaging and apparent diffusion coefficient (dWI/AdC) 
sequence Tr/Te = 4400/105 ms, slice thickness 5 mm. As 
MrI contrast agent 10 ml of dotarem (gadolinium-tetraa-
zacyclododecanetetraacetic acid, Gd-doTA) was adminis-
tered. Computed tomography (CT) was performed using a 
10-row multidetector CT scanner (sensation 10, siemens 
Medical systems, erlangen, Germany) with a slice thick-
ness of 3 mm. As CT contrast agent 45 ml of ultravist was 
administered. The MrI and CT findings are demonstra-
ted in Fig. 1. The CT image after contrast administration 
displayed an enhancing mass adjacent to the frontal horn of 
the left lateral ventricle and MrI showed a predominantly 
T2-hyperintense mass with central nodular enhancement 
and surrounding T2 hyperintensity.
Fig. 1 An 8-year-old boy with pathologically documented giant cell 
glioblastoma. Contrast-enhanced axial (a) and coronal (b) T1-weight-
ed magnetic resonance imaging (MrI) and axial postcontrast com-
puted tomography (CT, c) images demonstrate an enhancing mass 
centered at the anterior limb of the left internal capsule. (d) Axial T2-
weighted MrI image reveals moderate surrounding T2 hyperintensity 
consistent with tumor and edema involving the basal ganglia and the 
internal and external capsules and compressing the anterior horn of 
the left ventricle. (e) diffusion-weighted image (dWI) signal intensity 
increases in the tumor corresponding to T2 signal changes (edema and 
T2 shine through). The semilunar T1 contrast-enhancing part has very 
low dWI signals corresponding to facilitated diffusion and indicating 
reduced cellularity. (f) Corresponding apparent diffusion coefficient 
(AdC) map. The AdC value setting a region of interest of 150 mm2 
within the tumor was 1168.5 ± 1.7 as mean value with a range between 
976 (minimum value) and 1313 (maximal value)
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A stereotactic biopsy revealed a GCG with typical p53 
accumulation in immunohistochemical staining indicating 
presence of Tp53 mutation in the tumor as demonstrated in 
Fig. 2. Focal necrosis and beginning endothelial prolifera-
tion were identified, typical features to differentiate a GBM 
from an anaplastic WHo III glioma. expression of glial 
fibrillary acidic protein (GFAp) and microtubule-associated 
protein 2 (MAp-2) was evident and the Ki-67 marker deter-
mined a proliferation rate of 20% (not shown). The diagno-
sis of GCG was confirmed by the Brain Tumor reference 
Center of the German society of neuropathology and neu-
roanatomy at the University Hospital of Bonn, Germany.
Discussion
Giant cell glioblastoma is a rare subtype of GBM and the 
diagnosis of GCG has significant clinical consequences. 
Children with a malignant glioma have a slightly better 
prognosis than their adult counterparts [9, 10]. In a collec-
tion consisting of 39 pediatric patients with supratentorial 
and cerebellar malignant gliomas, including 1 GCG, the 
extent of resection was the strongest predictor of outcome 
[20]. In the case of a GCG where the prognosis seems to be 
better according to the current literature, maximum surgi-
cal resection with the combination of aggressive adjuvant 
radiochemotherapy (using for instance the protocols of the 
HIT-GBM trials [19]) may lead to better outcome. Howe-
ver, a previous publication could not confirm a better overall 
survival and event-free survival in pediatric GCGs compa-
red to GBM [19]. The GCGs are of glial origin [21] and the-
refore stain positively for GFAp. nuclear p53 accumulation 
was detected in the biopsy, indicating a Tp53 mutation con-
sistent with previous work on the genetic profile of GCGs 
with a p53 mutation frequency of more than 70% whereas 
epidermal growth factor receptor (eGFr) amplification was 
found very rarely [22, 23]. The detected proliferation rate 
for the antibody against ki67 was also consistent with previ-
ous case reports determining similar or the same prolifera-
tion index of 20% as in this case [4].
The differential diagnosis based on imaging and clinical 
presentation is broad, including low-grade tumors, such as 
ganglioglioma, pleomorphic xanthoastrocytoma, and oli-
godendroglioma. High-grade neoplasms and infections can 
Fig. 2 (a) Histologically the 
brain biopsy showed a cellular, 
mitotically active glial tumor 
(a: original magnification x40) 
and (b, c) bizarre, occasionally 
multinucleated giant tumor cells 
were also seen. (d) Immuno-
histochemically a pronounced 
nuclear p53 accumulation was 
present in most tumor cells. 
(b–d: original magnification 
x200) staining: a–c: hematoxy-
lin and eosin; d: immunohisto-
chemical staining for p53
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also have a similar appearance. due to the fact that seizures 
and headache are very common and non-specific symptoms 
occur in different brain tumors, it is crucial to perform radio-
logical scrutiny to narrow the diagnosis to improve patient 
management prior to treatment or biopsy.
In this case the radiological findings of an exceedingly 
rare primary brain tumor, a GCG, a GBM subtype probably 
with a better prognosis are presented. Central homogeneous 
enhancement is present, different than the heterogeneous 
peripheral enhancement often seen in classical GBMs. The 
contrast-enhancing part revealed a low signal on dWI indi-
cating reduced cellularity.
Larger studies evaluating imaging findings in GCGs are 
needed to determine if these imaging characteristics are typi- 
cal of GCGs and can help distinguish GBMs from GCGs. Alt-
hough rare preoperative consideration of this entity should 
be included when radiologically and clinically appropriate 
which in turn might impact different patient care in pediatric 
GCGs and GBMs. In a retrospective analysis significantly 
more pediatric patients with GCG were treated according to 
the HIT-GBM-d protocol, a very intensive chemotherapy 
regimen, compared to pediatric GBM patients [19]. This 
study described the use of different neurooncological tre-
atment protocols for GBM and GCG. The outcome of the 
GCG patients treated with the more intensive chemotherapy 
regimen was not analyzed. Hence further investigations are 
necessary in terms of an outcome benefit in GCG before 
a more intensive chemotherapy regimen can be justified. 
nevertheless it is crucial to consider that histological confir-
mation of the exact diagnosis is required before appropriate 
treatment decisions can be made.
Conclusions
preoperative consideration of a GCG should be included in 
pediatric patients when radiologically and clinically appro-
priate as well as histologically proven which in turn might 
influence future therapy approaches towards a more inten-
sive chemotherapy regimen. To the best of our knowledge 
this is the first manuscript demonstrating MrI and CT fin-
dings in a patient with GCG.
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